Mamede de Carvalho

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1223735/publications.pdf

Version: 2024-02-01

375 papers	14,964 citations	34105 52 h-index	26613 107 g-index
387 all docs	387 docs citations	387 times ranked	13323 citing authors

#	Article	IF	Citations
1	Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clinical Neurophysiology, 2014, 125, 2150-2206.	1.5	1,647
2	Electrodiagnostic criteria for diagnosis of ALS. Clinical Neurophysiology, 2008, 119, 497-503.	1.5	927
3	EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) â€“ revised report of an EFNS task force. European Journal of Neurology, 2012, 19, 360-375.	3.3	860
4	Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nature Neuroscience, 2015, 18, 631-636.	14.8	652
5	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
6	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
7	Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology, The, 2013, 12, 310-322.	10.2	454
8	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	10.2	342
9	A proposal for new diagnostic criteria for ALS. Clinical Neurophysiology, 2020, 131, 1975-1978.	1.5	268
10	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
11	Awaji Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. Archives of Neurology, 2012, 69, 1410.	4.5	211
12	Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 53-57.	2.1	196
13	Hot-spot KIF5A mutations cause familial ALS. Brain, 2018, 141, 688-697.	7.6	167
14	Clinical and genetic characterization of families with triple A (Allgrove) syndrome. Brain, 2002, 125, 2681-2690.	7.6	137
15	Nerve conduction studies in amyotrophic lateral sclerosis. , 2000, 23, 344-352.		136
16	Motor neuron disease presenting with respiratory failure. Journal of the Neurological Sciences, 1996, 139, 117-122.	0.6	132
17	Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Human Molecular Genetics, 2011, 20, 1697-1700.	2.9	127
18	Home telemonitoring of non-invasive ventilation decreases healthcare utilisation in a prospective controlled trial of patients with amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1238-1242.	1.9	123

#	Article	IF	Citations
19	Pathophysiology inferred from electrodiagnostic nerve tests and classification of polyneuropathies. Suggested guidelines. Clinical Neurophysiology, 2005, 116, 1571-1580.	1.5	122
20	Generalised sensory system abnormalities in amyotrophic lateral sclerosis: a European multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 746-749.	1.9	121
21	A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions inC9orf72reveals marked differences in results among 14 laboratories. Journal of Medical Genetics, 2014, 51, 419-424.	3.2	118
22	Clinical variability in type I familial amyloid polyneuropathy (Val30Met): Comparison between late- and early-onset cases in Portugal. Muscle and Nerve, 2007, 35, 116-118.	2.2	113
23	Motor Unit Number Index (MUNIX): A novel neurophysiological marker for neuromuscular disorders; testâ€“retest reliability in healthy volunteers. Clinical Neurophysiology, 2011, 122, 1867-1872.	1.5	106
24	A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 456-460.	2.1	101
25	Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): a 15-month longitudinal multicentre trial. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1172-1179.	1.9	97
26	Repetitive nerve stimulation in myasthenia gravisâ€"relative sensitivity of different muscles. Clinical Neurophysiology, 2004, 115, 2776-2782.	1.5	96
27	Nocturnal pulse oximetry: a new approach to establish the appropriate time for nonâ€invasive ventilation in ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 31-35.	1.2	95
28	Fasciculation potentials and earliest changes in motor unit physiology in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 963-968.	1.9	93
29	Fasciculation potentials: A study of amyotrophic lateral sclerosis and other neurogenic disorders. , 1998, 21, 336-344.		90
30	Can amyotrophic lateral sclerosis patients with respiratory insufficiency exercise?. Journal of the Neurological Sciences, 1999, 169, 69-75.	0.6	88
31	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.7	84
32	Motor unit number estimation (MUNE): Where are we now?. Clinical Neurophysiology, 2018, 129, 1507-1516.	1.5	79
33	Reduced Myocardial 123-Iodine Metaiodobenzylguanidine Uptake. Circulation: Cardiovascular Imaging, 2013, 6, 627-636.	2.6	78
34	Ultrasound for assessment of diaphragm in ALS. Clinical Neurophysiology, 2016, 127, 892-897.	1.5	76
35	Fasciculation in amyotrophic lateral sclerosis: origin and pathophysiological relevance. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 773-779.	1.9	76
36	Sleep characteristics of amyotrophic lateral sclerosis in patients with preserved diaphragmatic function. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 101-105.	2.1	75

#	Article	IF	Citations
37	Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data. Clinical Neurophysiology, 2016, 127, 2684-2691.	1.5	74
38	Predicting respiratory insufficiency in amyotrophic lateral sclerosis: The role of phrenic nerve studies. Clinical Neurophysiology, 2009, 120, 941-946.	1.5	72
39	Neurophysiological measures in amyotrophic lateral sclerosis: Markers of progression in clinical trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 17-28.	2.1	71
40	Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology, 2018, 91, e1999-e2009.	1.1	70
41	Nocturnal pulse oximetry: a new approach to establish the appropriate time for non-invasive ventilation in ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 31-35.	1.2	67
42	Cramps, muscle pain, and fasciculations. Neurology, 2004, 63, 721-723.	1.1	63
43	Delayed diagnosis in ALS: The problem continues. Journal of the Neurological Sciences, 2014, 343, 173-175.	0.6	63
44	A new method for reproducible coil positioning in transcranial magnetic stimulation mapping. Electroencephalography and Clinical Neurophysiology - Electromyography and Motor Control, 1997, 105, 116-123.	1.4	62
45	Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 344-350.	1.7	62
46	Lower motor neuron dysfunction in ALS. Clinical Neurophysiology, 2016, 127, 2670-2681.	1.5	62
47	Magnetic stimulation in Alzheimer's disease. Journal of Neurology, 1997, 244, 304-307.	3.6	60
48	Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 126-133.	3.0	59
49	Quantitating progression in ALS. Neurology, 2005, 64, 1783-1785.	1.1	59
50	Phrenic nerve studies predict survival in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2012, 123, 2454-2459.	1.5	59
51	Exercise and amyotrophic lateral sclerosis. Neurological Sciences, 2012, 33, 9-15.	1.9	58
52	Changes of the phrenic nerve motor response in amyotrophic lateral sclerosis: Longitudinal study. Clinical Neurophysiology, 2009, 120, 2082-2085.	1.5	56
53	Respiratory exercise in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 33-43.	2.1	56
54	The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy. Clinical Neurophysiology, 2016, 127, 2222-2227.	1.5	56

#	Article	IF	Citations
55	Motor Unit Number Index (MUNIX) detects motor neuron loss in pre-symptomatic muscles in Amyotrophic Lateral Sclerosis. Clinical Neurophysiology, 2017, 128, 495-500.	1.5	56
56	Quality of life in amyotrophic lateral sclerosis patients and caregivers: Impact of assistive communication from early stages. Muscle and Nerve, 2015, 52, 933-941.	2.2	55
57	The Neurophysiological Index in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 108-110.	1.2	54
58	Motor responses evoked by transcranial magnetic stimulation and peripheral nerve stimulation in the ulnar innervation in amyotrophic lateral sclerosis: the effect of upper and lower motor neuron lesion. Journal of the Neurological Sciences, 2003, 210, 83-90.	0.6	53
59	Replication study of MATR3 in familial and sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2016, 37, 209.e17-209.e21.	3.1	53
60	Paralytic shellfish poisoning: clinical and electrophysiological observations. Journal of Neurology, 1998, 245, 551-554.	3.6	51
61	Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis. Journal of Neurology, 2008, 255, 545-550.	3.6	51
62	Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron, 2022, 110, 992-1008.e11.	8.1	51
63	Does caffeine modify corticomotor excitability?. Neurophysiologie Clinique, 2006, 36, 219-226.	2.2	48
64	Does surgery accelerate progression of amyotrophic lateral sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 643-646.	1.9	48
65	Associated movement disorders in orthostatic tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 725-729.	1.9	46
66	Diagnostic criteria for amyotrophic lateral sclerosis: A multicentre study of inter-rater variation and sensitivity. Clinical Neurophysiology, 2019, 130, 307-314.	1.5	46
67	Roles of Vascular Endothelial Growth Factor in Amyotrophic Lateral Sclerosis. BioMed Research International, 2014, 2014, 1-24.	1.9	45
68	Epidemiology of Transthyretin Familial Amyloid Polyneuropathy in Portugal: A Nationwide Study. Neuroepidemiology, 2018, 51, 177-182.	2.3	45
69	Amyotrophic lateral sclerosis. Current Opinion in Neurology, 2011, 24, 497-503.	3.6	44
70	Respiratory measures in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 321-330.	1.7	44
71	Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis. Muscle and Nerve, 2003, 28, 630-633.	2.2	43
72	Association of paraspinal and diaphragm denervation in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 63-66.	2.1	43

#	Article	IF	Citations
73	Motor Unit Number Index (MUNIX): Reference values of five different muscles in healthy subjects from a multi-centre study. Clinical Neurophysiology, 2011, 122, 1895-1898.	1.5	43
74	Correlation between Forced Vital Capacity and Slow Vital Capacity for the assessment of respiratory involvement in Amyotrophic Lateral Sclerosis: a prospective study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 86-91.	1.7	42
75	Percutaneous nocturnal oximetry in amyotrophic lateral sclerosis: Periodic desaturation. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 154-161.	2.1	41
76	Paralytic shellfish poisoning due to ingestion of Gymnodinium catenatum contaminated cockles â€“ Application of the AOAC HPLC Official Method. Toxicon, 2012, 59, 558-566.	1.6	41
77	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.7	41
78	Quality Control of Motor Unit Number Index (MUNIX) Measurements in 6 Muscles in a Single-Subject â€œRound-Robinâ€•Setup. PLoS ONE, 2016, 11, e0153948.	2.5	40
79	Diaphragmatic Neurophysiology and Respiratory Markers in ALS. Frontiers in Neurology, 2019, 10, 143.	2.4	38
80	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264.	12.4	38
81	Allgrove syndrome in adulthood. Muscle and Nerve, 2001, 24, 292-296.	2.2	37
82	Clinical trials in ALS: A review of the role of clinical and neurophysiological measurements. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 202-212.	2.1	37
83	Sensitivity of electrophysiological tests for upper and lower motor neuron dysfunction in ALS: A sixâ€•month longitudinal study. Muscle and Nerve, 2010, 41, 208-211.	2.2	37
84	Economic cost of home-telemonitoring care for BiPAP-assisted ALS individuals. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 533-537.	2.1	37
85	Pathophysiological significance of fasciculations in the early diagnosis of ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, S43-S46.	1.2	36
86	Motor responses of the sternocleidomastoid muscle in patients with amyotrophic lateral sclerosis. Muscle and Nerve, 2008, 38, 1312-1317.	2.2	36
87	Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients. Neurodegenerative Disease Management, 2014, 4, 83-102.	2.2	36
88	Youngâ€•onset sporadic amyotrophic lateral sclerosis: A distinct nosological entity?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 323-327.	2.1	35
89	What is the relevance of percutaneous endoscopic gastrostomy on the survival of patients with amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 550-554.	2.1	35
90	Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 668-678.	1.9	35

#	Article	IF	Citations
91	Vestibulo-ocular reflex dynamics withÂhead-impulses discriminates spinocerebellar ataxias types 1, 2 and 3 andÂFriedreich ataxia. Journal of Vestibular Research: Equilibrium and Orientation, 2016, 26, 327-334.	2.0	34
92	Spreading in ALS: The relative impact of upper and lower motor neuron involvement. Annals of Clinical and Translational Neurology, 2020, 7, 1181-1192.	3.7	34
93	Diagnosis, Pathogenesis and Therapeutic Targets in Amyotrophic Lateral Sclerosis. CNS and Neurological Disorders - Drug Targets, 2010, 9, 764-778.	1.4	34
94	Cortical muscle representation in amyotrophic lateral sclerosis patients: Changes with disease evolution. Muscle and Nerve, 1999, 22, 1684-1692.	2.2	33
95	Implementation of a Wireless Device for Real-Time Telemedical Assistance of Home-Ventilated Amyotrophic Lateral Sclerosis Patients: A Feasibility Study. Telemedicine Journal and E-Health, 2010, 16, 883-888.	2.8	33
96	Gelsolin-related familial amyloidosis, Finnish type, in a Portuguese family: Clinical and neurophysiological studies. Muscle and Nerve, 2003, 28, 715-721.	2.2	32
97	Can Selection of Rapidly Progressing Patients Shorten Clinical Trials in Amyotrophic Lateral Sclerosis?. Archives of Neurology, 2006, 63, 557.	4.5	32
98	Decreased heart rate variability predicts death in amyotrophic lateral sclerosis. Muscle and Nerve, 2012, 46, 341-345.	2.2	32
99	Origin of Fasciculations in Amyotrophic Lateral Sclerosis and Benign Fasciculation Syndrome. JAMA Neurology, 2013, 70, 1562-5.	9.0	32
100	Fasciculation discharge frequency in amyotrophic lateral sclerosis and related disorders. Clinical Neurophysiology, 2016, 127, 2257-2262.	1.5	32
101	Neurophysiological features of fasciculation potentials evoked by transcranial magnetic stimulation in amyotrophic lateral sclerosis. Journal of Neurology, 2000, 247, 189-194.	3.6	31
102	Neurophysiological markers in familial amyloid polyneuropathy patients: Early changes. Clinical Neurophysiology, 2008, 119, 1082-1087.	1.5	31
103	Paraspinal and limb motor neuron involvement within homologous spinal segments in ALS. Clinical Neurophysiology, 2008, 119, 1607-1613.	1.5	31
104	The R of ALSFRS-R: Does it really mirror functional respiratory involvement in amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 120-123.	1.7	31
105	Understanding the use of NIV in ALS: results of an international ALS specialist survey. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 331-341.	1.7	31
106	F-Waves and the corticospinal lesion in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, 131-136.	1.2	30
107	Motoneuron firing in amyotrophic lateral sclerosis (ALS). Frontiers in Human Neuroscience, 2014, 8, 719.	2.0	30
108	Neurophysiological techniques to detect early smallâ€fiber dysfunction in transthyretin amyloid polyneuropathy. Muscle and Nerve, 2014, 49, 181-186.	2.2	30

#	Article	IF	Citations
109	Comparison of slow and forced vital capacities on ability to predict survival in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 528-533.	1.7	30
110	Respiratory disorders in ALS: sleep and exercise studies. Journal of the Neurological Sciences, 1999, 169, 61-68.	0.6	29
111	Emerging molecular biomarker targets for amyotrophic lateral sclerosis. Clinica Chimica Acta, 2016, 455, 7-14.	1.1	29
112	The Role of Moderate Aerobic Exercise as Determined by Cardiopulmonary Exercise Testing in ALS. Neurology Research International, 2018, 2018, 1-10.	1.3	29
113	Interleukin-6 and amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2019, 398, 50-53.	0.6	29
114	Fibrillation and sharp-waves: Do we need them to diagnose ALS?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, 29-32.	1.2	28
115	Clinical patterns in progressive muscular atrophy (PMA): A prospective study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 296-299.	2.1	28
116	Multifocal motor neuropathy mimicking motor neuron disease: nine cases. Journal of the Neurological Sciences, 1999, 169, 76-79.	0.6	27
117	Motor unit firing in amyotrophic lateral sclerosis and other upper and lower motor neurone disorders. Clinical Neurophysiology, 2012, 123, 2312-2318.	1.5	27
118	Prognostic models based on patient snapshots and time windows: Predicting disease progression to assisted ventilation in Amyotrophic Lateral Sclerosis. Journal of Biomedical Informatics, 2015, 58, 133-144.	4.3	27
119	Transcutaneous spinal direct current stimulation of the lumbar and sacral spinal cord: a modelling study. Journal of Neural Engineering, 2018, 15, 036008.	3.5	27
120	Muscular cramp: causes and management. European Journal of Neurology, 2019, 26, 214-221.	3.3	27
121	Reproducibility of neurophysiological and myometric measurement in the ulnar nerve-abductor digiti minimi system. Muscle and Nerve, 2001, 24, 1391-1395.	2.2	26
122	Motor-axonal polyneuropathy associated with hepatitis C virus. European Journal of Neurology, 2003, 10, 183-185.	3.3	26
123	Pain and calf hypertrophy associated with spontaneous repetitive discharges treated with botulinum toxin. Clinical Neurophysiology, 2005, 116, 2847-2852.	1.5	26
124	Occasional essay: Upper motor neuron syndrome in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 227-234.	1.9	26
125	Acquired amyloid neuropathy in a Portuguese patient after domino liver transplantation. Muscle and Nerve, 2010, 42, 836-838.	2.2	25
126	Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis. Clinica Chimica Acta, 2015, 438, 342-349.	1.1	25

#	Article	IF	Citations
127	Phrenic nerve stimulation is more sensitive than ultrasound measurement of diaphragm thickness in assessing early ALS progression. Neurophysiologie Clinique, 2017, 47, 69-73.	2.2	25
128	Split-hand and split-limb phenomena in amyotrophic lateral sclerosis: pathophysiology, electrophysiology and clinical manifestations. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1126-1130.	1.9	25
129	Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene. Cell Reports, 2020, 33, 108456.	6.4	24
130	Sensitivity of MUP parameters in detecting change in early ALS. Clinical Neurophysiology, 2014, 125, 166-169.	1.5	23
131	Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. Journal of Neurology, 2020, 267, 2130-2141.	3.6	23
132	Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. Npj Genomic Medicine, 2022, 7, 8.	3.8	23
133	Variation in diagnostic strategy of the EMG examinationâ€“a multicentre study. Clinical Neurophysiology, 1999, 110, 1814-1824.	1.5	22
134	The Awaji criteria for diagnosis of ALS. Muscle and Nerve, 2011, 44, 456-456.	2.2	22
135	Prognosis of phrenic nerve injury following thoracic interventions: Four new cases and a review. Clinical Neurology and Neurosurgery, 2012, 114, 199-204.	1.4	22
136	Reconsidering the causality of TIA1 mutations in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 1-3.	1.7	22
137	Exploring Cerebrospinal Fluid IgG N-Glycosylation as Potential Biomarker for Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2019, 56, 5729-5739.	4.0	22
138	SVC Is a Marker of Respiratory Decline Function, Similar to FVC, in Patients With ALS. Frontiers in Neurology, 2019, 10, 109.	2.4	22
139	Gold Coast diagnostic criteria increase sensitivity in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2021, 132, 3183-3189.	1.5	22
140	Monomelic neurogenic syndromes: A prospective study. Journal of the Neurological Sciences, 2007, 263, 26-34.	0.6	21
141	Finite element studies of the mechanical behaviour of the diaphragm in normal and pathological cases. Computer Methods in Biomechanics and Biomedical Engineering, 2011, 14, 505-513.	1.6	21
142	Mutant fibrinogen A-Î±-chain associated with hereditary renal amyloidosis and peripheral neuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2004, 11, 200-207.	3.0	20
143	Upper limb tremor induced by peripheral nerve injury. Neurology, 2006, 67, 1884-1886.	1.1	20
144	Can inspiratory muscle training increase survival in early-affected amyotrophic lateral sclerosis patients?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 124-126.	1.7	20

#	Article	IF	Citations
145	A prospective multicentre study on sural nerve action potentials in ALS. Clinical Neurophysiology, 2008, 119, 1106-1110.	1.5	19
146	Fasciculation-cramp syndrome preceding anterior horn cell disease: an intermediate syndrome?. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 459-461.	1.9	19
147	Early diagnosis of amyotrophic lateral sclerosis by threshold tracking and conventional transcranial magnetic stimulation. European Journal of Neurology, 2021, 28, 3030-3039.	3.3	19
148	New transthyretin mutation V28M in a Portuguese kindred with amyloid polyneuropathy. Muscle and Nerve, 2000, 23, 1016-1021.	2.2	18
149	Amplitude, area and duration of the compound muscle action potential change in different ways over the length of the ulnar nerve. Clinical Neurophysiology, 2006, 117, 2085-2092.	1.5	18
150	Amyotrophic lateral sclerosis patients and ocular ptosis. Clinical Neurology and Neurosurgery, 2008, 110, 168-170.	1.4	18
151	Influence of Environment and Lifestyle on Incidence and Progress of Amyotrophic Lateral Sclerosis in A German ALS Population. , 2019, 10, 205.		18
152	The onset of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 77, 388-389.	1.9	17
153	Lesion of the deep palmar branch of the ulnar nerve: Causes and clinical outcome. Neurophysiologie Clinique, 2010, 40, 159-164.	2.2	17
154	Electrophysiological Studies in Healthy Subjects Involving Caffeine. Journal of Alzheimer's Disease, 2010, 20, S63-S69.	2.6	17
155	Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 256-264.	1.7	17
156	International Survey of ALS Experts about Critical Questions for Assessing Patients with ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 505-510.	1.7	17
157	Reflex sympathetic dystrophy associated with amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 1999, 169, 80-83.	0.6	16
158	What Is Really New in Progressive Muscle Atrophy?. Archives of Neurology, 2009, 66, 1427.	4.5	16
159	Neurologic complications of craniovertebral dislocation. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 119, 435-448.	1.8	16
160	Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Scientific Reports, 2017, 7, 44709.	3.3	16
161	The split hand in amyotrophic lateral sclerosis: a possible role for the neuromuscular junction. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 368-375.	1.7	16
162	Increased creatine kinase and spontaneous activity on electromyography, in amyotrophic lateral sclerosis. Electromyography and Clinical Neurophysiology, 2003, 43, 189-92.	0.2	16

#	Article	IF	Citations
163	The corticomotor threshold is not dependent on disease duration in amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, 39-42.	1.2	15
164	Proteomic analysis of plasma from Portuguese patients with familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 339-349.	2.1	15
165	Motor unit changes in thoracic paraspinal muscles in amyotrophic lateral sclerosis. Muscle and Nerve, 2009, 39, 83-86.	2.2	15
166	Does the motor cortex influence denervation in ALS? EMG studies of muscles with both contralateral and bilateral corticospinal innervation. Clinical Neurophysiology, 2011, 122, 629-635.	1.5	15
167	Muscle ultrasound detects fasciculations and facilitates diagnosis in ALS. Neurology, 2011, 77, 1508-1509.	1.1	15
168	Testing upper motor neuron function in amyotrophic lateral sclerosis: the most difficult task of neurophysiology. Brain, 2012, 135, 2581-2582.	7.6	15
169	Phosphoneurofilament heavy chain and vascular endothelial growth factor as cerebrospinal fluid biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 134-136.	1.7	15
170	Sympathetic sudomotor function and amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2001, 2, 105-108.	1.2	14
171	Variation in the classification of polyneuropathies among European physicians. Clinical Neurophysiology, 2003, 114, 496-503.	1.5	14
172	Symmetry of phrenic nerve motor response in amyotrophic lateral sclerosis. Muscle and Nerve, 2010, 42, 822-824.	2.2	14
173	Primary lateral sclerosis: Predicting functional outcome. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 141-145.	1.7	14
174	Young-onset rapidly progressive ALS associated with heterozygous FUS mutation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 451-453.	1.7	14
175	Beyond fractional anisotropy in amyotrophic lateral sclerosis: the value of mean, axial, and radial diffusivity and its correlation with electrophysiological conductivity changes. Neuroradiology, 2018, 60, 505-515.	2.2	14
176	Cervical trans-spinal direct current stimulation: a modelling-experimental approach. Journal of NeuroEngineering and Rehabilitation, 2019, 16, 123.	4.6	14
177	C9orf72 expansion is associated with accelerated decline of respiratory function and decreased survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 118-120.	1.9	14
178	Electrodiagnosis of Amyotrophic Lateral Sclerosis: A Review of Existing Guidelines. Journal of Clinical Neurophysiology, 2020, 37, 294-298.	1.7	14
179	Orofacial Apraxia in Motor Neuron Disease. Case Reports in Neurology, 2013, 5, 47-51.	0.7	13
180	Identification of erythrocyte biomarkers in amyotrophic lateral sclerosis. Clinical Hemorheology and Microcirculation, 2016, 63, 423-437.	1.7	13

#	Article	IF	Citations
181	Assessment of the reliability of the motor unit size index (MUSIX) in single subject â€œround-robinâ€•and multi-centre settings. Clinical Neurophysiology, 2019, 130, 666-674.	1.5	13
182	Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 126-33.	3.0	13
183	Respiratory apraxia in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 180-184.	2.1	12
184	Machado-Joseph disease presenting as motor neuron disease. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 188-191.	2.1	12
185	Vascular endothelial growth factor and amyotrophic lateral sclerosis: The interplay with exercise and noninvasive ventilation. Muscle and Nerve, 2014, 49, 545-550.	2.2	12
186	Markers for upper limb dysfunction in Amyotrophic Lateral Sclerosis using analysis of typing activity. Clinical Neurophysiology, 2016, 127, 925-931.	1.5	12
187	Added value of electromyography in the diagnosis of myopathy: A consensus exercise. Clinical Neurophysiology, 2017, 128, 697-701.	1.5	12
188	Physiology of the fasciculation potentials in amyotrophic lateral sclerosis: which motor units fasciculate?. Journal of Physiological Sciences, 2017, 67, 569-576.	2.1	12
189	Neuromodulation of lower limb motor responses with transcutaneous lumbar spinal cord direct current stimulation. Clinical Neurophysiology, 2018, 129, 1999-2009.	1.5	12
190	A comparative study of South African and Portuguese amyotrophic lateral sclerosis cohorts. Journal of the Neurological Sciences, 2020, 414, 116857.	0.6	12
191	Delayed Diagnosis and Diagnostic Pathway of ALS Patients in Portugal: Where Can We Improve?. Frontiers in Neurology, 2021, 12, 761355.	2.4	12
192	Choreaâ€acanthocytosis presenting as motor neuron disease. Muscle and Nerve, 2012, 45, 293-295.	2.2	11
193	No association between VAPB mutations and familial or sporadic ALS in Sweden, Portugal and Iceland. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 620-627.	1.7	11
194	Rapidly progressive frontotemporal dementia and bulbar amyotrophic lateral sclerosis in Portuguese patients with C9orf72 mutation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 70-72.	1.7	11
195	Modulation of fasciculation frequency in amyotrophic lateral sclerosis: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309686.	1.9	11
196	Anticompensatory quick eye movements after head impulses: A peripheral vestibular sign in spontaneous nystagmus. Journal of Vestibular Research: Equilibrium and Orientation, 2016, 25, 267-271.	2.0	11
197	Diaphragm motor responses to phrenic nerve stimulation in ALS: Surface and needle recordings. Clinical Neurophysiology, 2018, 129, 349-353.	1.5	11
198	Sniff nasal inspiratory pressure (SNIP) in amyotrophic lateral sclerosis: Relevance of the methodology for respiratory function evaluation. Clinical Neurology and Neurosurgery, 2018, 171, 42-45.	1.4	11

#	Article	IF	Citations
199	Potential Preventive Strategies for Amyotrophic Lateral Sclerosis. Frontiers in Neuroscience, 2020, 14, 428.	2.8	11
200	Neurophysiological features of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 11-17.	1.7	11
201	Randomised controlled trial in non-invasive ventilation: what trial?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 255-256.	1.2	10
202	Hereditary sensory neuropathy type 1 in a Portuguese familyâ€"electrodiagnostic and autonomic nervous system studies. Journal of the Neurological Sciences, 2004, 227, 35-38.	0.6	10
203	Sialorrhoea and reversals in ALS functional rating scale. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 187-188.	1.9	10
204	The Effect of <scp>SMN</scp> Gene Dosage on <scp>ALS</scp> Risk and Disease Severity. Annals of Neurology, 2021, 89, 686-697.	5.3	10
205	Cardiovascular comorbidities in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2021, 421, 117292.	0.6	10
206	Learning dynamic Bayesian networks from time-dependent and time-independent data: Unraveling disease progression in Amyotrophic Lateral Sclerosis. Journal of Biomedical Informatics, 2021, 117, 103730.	4.3	10
207	Can medical audit change electromyographic practice?. Electroencephalography and Clinical Neurophysiology - Electromyography and Motor Control, 1998, 109, 496-501.	1.4	9
208	Medical technology assessment Electrodiagnosis in motor neuron diseases and amyotrophic lateral sclerosis. Neurophysiologie Clinique, 2001, 31, 341-348.	2.2	9
209	Influence of medical audit on electrodiagnostic evaluation of polyneuropathy. A multicentre study. Clinical Neurophysiology, 2005, 116, 49-55.	1.5	9
210	Influence of peer review medical audit on pathophysiological interpretation of nerve conduction studies in polyneuropathies. Clinical Neurophysiology, 2006, 117, 979-983.	1.5	9
211	Abnormal transcranial magnetic stimulation in a patient with presumed psychogenic paralysis. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1412-1413.	1.9	9
212	A 3-month-old baby with H1N1 and Guillain-Barre syndrome. BMJ Case Reports, 2012, 2012, bcr1220115462-bcr1220115462.	0.5	9
213	Motor excitability measurements: The influence of gender, body mass index, age and temperature in healthy controls. Neurophysiologie Clinique, 2014, 44, 213-218.	2.2	9
214	Distal myopathy and rapidly progressive dementia associated with a novel mutation in the VCP gene: Expanding inclusion body myopathy with early-onset Paget disease and frontotemporal dementia spectrum. Journal of Clinical Neuroscience, 2019, 64, 8-10.	1.5	9
215	Transforming growth factor-Î² plasma levels and its role in amyotrophic lateral sclerosis. Medical Hypotheses, 2020, 139, 109632.	1.5	9
216	Familial clustering of primary lateral sclerosis and amyotrophic lateral sclerosis: Supplementary evidence for a continuum. European Journal of Neurology, 2021, 28, 2780-2783.	3.3	9

#	Article	IF	Citations
217	Percutaneous gastrostomy in amyotrophic lateral sclerosis: a review. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 176-189.	1.7	9
218	Clinical and therapeutic implications of presymptomatic gene testing for familial amyloidotic polyneuropathy (FAP). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 26-31.	3.0	8
219	Epileptic seizures as a presentation of central nervous system involvement in TTR Val30Met-FAP. Journal of Neurology, 2016, 263, 2336-2338.	3.6	8
220	Clinical characteristics in young-adult ALS â€“ results from a Portuguese cohort study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 620-623.	1.7	8
221	AANEM â€“ IFCN glossary of terms in neuromuscular electrodiagnostic medicine and ultrasound. Clinical Neurophysiology, 2020, 131, 1662-1663.	1.5	8
222	The cutaneous silent period in motor neuron disease. Clinical Neurophysiology, 2021, 132, 660-665.	1.5	8
223	The senile hand: Age effects on intrinsic hand muscle <scp>CMAP</scp> amplitudes influence splitâ€hand index calculations. Muscle and Nerve, 2022, 65, 463-467.	2.2	8
224	Electrodiagnostic assessment of respiratory dysfunction in motor neuron disease. Handbook of Clinical Neurophysiology, 2004, , 513-528.	0.0	7
225	Evidence for central abnormality in respiratory control in primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2006, 7, 57-60.	2.1	7
226	Erythropoietin and amyotrophic lateral sclerosis: Plasma level determination. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 439-443.	2.1	7
227	Is it better than it seems or just good enough? The tafamidis saga. Muscle and Nerve, 2012, 46, 14-14.	2.2	7
228	Tackling diagnostic delays in ALS. Lancet Neurology, The, 2015, 14, 457-458.	10.2	7
229	Riluzole-induced recurrent pancreatitis. Journal of Clinical Neuroscience, 2017, 45, 153-154.	1.5	7
230	Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 506-512.	1.7	7
231	Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions. Lancet Neurology, The, 2018, 17, 842.	10.2	7
232	Frequency of C9orf72 hexanucleotide repeat expansion and SOD1Âmutations in Portuguese patients with amyotrophic lateralÂsclerosis. Neurobiology of Aging, 2018, 70, 325.e7-325.e15.	3.1	7
233	Tele-monitoring of a home-based exercise program in amyotrophic lateral sclerosis: a feasibility study. European Journal of Physical and Rehabilitation Medicine, 2018, 54, 501-503.	2.2	7
234	VRK1 variants in two Portuguese unrelated patients with childhood-onset motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 291-295.	1.7	7

#	Article	IF	Citations
235	Mouth occlusion pressure at 100ms (P0.1) as a respiratory biomarker in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 53-60.	1.7	7
236	Motor neuron disease beginning with frontotemporal dementia: clinical features and progression. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 508-516.	1.7	7
237	Explainable models of disease progression in ALS: Learning from longitudinal clinical data with recurrent neural networks and deep model explanation. Computer Methods and Programs in Biomedicine Update, 2021, 1, 100018.	3.7	7
238	Do bulbar-onset amyotrophic lateral sclerosis patients have an earlier respiratory involvement than spinal-onset amyotrophic lateral sclerosis patients?. Europa Medicophysica, 2007, 43, 505-9.	0.5	7
239	Respiratory onset in amyotrophic lateral sclerosis: clinical features and spreading pattern. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 40-44.	1.7	7
240	Biochemical characterization of plasma in amyotrophic lateral sclerosis: Amino acid and protein composition. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 104-110.	2.1	6
241	Steroid-responsive demyelinating motor neuropathy with conduction block associated with hepatitis C infection and treatment with interferon alpha. Journal of the Peripheral Nervous System, 2006, 11, 353-354.	3.1	6
242	Accessory nerve stimulation: Motor response of the sternocleidomastoid muscle. Neurophysiologie Clinique, 2008, 38, 133-136.	2.2	6
243	Is a four-hour use of non-invasive ventilation enough to define compliance?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 250-252.	2.1	6
244	Fasciculation potentials: Still mysterious. Clinical Neurophysiology, 2012, 123, 227-228.	1.5	6
245	New insights into the clinical neurophysiological assessment of ALS. Neurophysiologie Clinique, 2016, 46, 157-163.	2.2	6
246	Very late-onset amyotrophic lateral sclerosis in a Portuguese cohort. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 619-622.	1.7	6
247	The impact of spasticity on diaphragm contraction: Electrophysiological assessment. Clinical Neurophysiology, 2018, 129, 1544-1550.	1.5	6
248	Mitochondrial Neurogastrointestinal Encephalomyopathy: Novel Pathogenic Mutation in Thymidine Phosphorylase Gene in a Patient from Cape Verde Islands. Case Reports in Neurological Medicine, 2019, 2019, 1-4.	0.4	6
249	Prevalence, Incidence, and Clinical-Epidemiological Characterization of Amyotrophic Lateral Sclerosis in Antioquia: Colombia. Neuroepidemiology, 2020, 54, 251-257.	2.3	6
250	Assessment of sympathetic sudomotor function in amyotrophic lateral sclerosis with electrochemical skin conductance. Clinical Neurophysiology, 2021, 132, 2032-2036.	1.5	6
251	Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients. European Journal of Neurology, 2018, 25, 1320.	3.3	6
252	Reinnervation as measured by the motor unit size index is associated with preservation of muscle strength in amyotrophic lateral sclerosis, but not all muscles reinnervate. Muscle and Nerve, 2022, 65, 203-210.	2.2	6

#	Article	IF	Citations
253	Electromyographic findings in primary lateral sclerosis during disease progression. Clinical Neurophysiology, 2021, 132, 2996-3001.	1.5	6
254	Reproducibility of corticomotor threshold: Some observations. , 1999, 22, 538-539.		5
255	Chronic inflammatory demyelinating polyneuropathy, phrenic nerve and respiratory symptoms. European Journal of Neurology, 2005, 12, 64-66.	3.3	5
256	Cerebrotendinous xanthomatosis: No involvement of the autonomic nervous system in a case with severe neuropathy. Neurophysiologie Clinique, 2007, 37, 47-49.	2.2	5
257	Myasthenia gravis and respiratory failure related to phrenic nerve lesion. Muscle and Nerve, 2008, 38, 1340-1341.	2.2	5
258	A case of asymptomatic cytoplasmic body myopathy revealed by sinvastatin. Neuromuscular Disorders, 2009, 19, 66-68.	0.6	5
259	Pseudobulbar syndrome in two patients with human immunodeficiency virus infection. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 220-222.	2.1	5
260	Variation in the neurophysiological examination of amyotrophic lateral sclerosis in Europe. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 443-448.	2.1	5
261	Implementation of an efficient muscle fatigue model in the framework of multibody systems dynamics for analysis of human movements. Proceedings of the Institution of Mechanical Engineers, Part K: Journal of Multi-body Dynamics, 2011, 225, 359-370.	0.8	5
262	Transthyretin familial amyloid polyneuropathy impact on health-related quality of life. Orphanet Journal of Rare Diseases, 2015, 10, O28.	2.7	5
263	Origin of fasciculations in root lesions. Clinical Neurophysiology, 2016, 127, 870-873.	1.5	5
264	The generator site in acquired autoimmune neuromyotonia. Clinical Neurophysiology, 2017, 128, 643-646.	1.5	5
265	Brain white matter demyelinating lesions and amyotrophic lateral sclerosis in a patient with C9orf72 hexanucleotide repeat expansion. Multiple Sclerosis and Related Disorders, 2017, 17, 1-4.	2.0	5
266	Novel TBK1 LoF variant in a family with upper motor neuron predominant motor neuron disease. Journal of the Neurological Sciences, 2019, 403, 117-118.	0.6	5
267	Diaphragmatic CMAP amplitude from phrenic nerve stimulation predicts functional decline in ALS. Journal of Neurology, 2020, 267, 2123-2129.	3.6	5
268	The yin and yang of gastrostomy in the management of ALS. Neurology, 2017, 89, 1435-1436.	1.1	5
269	Modelling Studies of Non-invasive Electric and Magnetic Stimulation of the Spinal Cord. , 2021, , 139-165.		5
270	Sensory potential can be preserved in severe common peroneal neuropathy. Electromyography and Clinical Neurophysiology, 2000, 40, 61-3.	0.2	5

#	Article	IF	Citations
271	Dynamic Bayesian Networks for stratification of disease progression in Amyotrophic Lateral Sclerosis. European Journal of Neurology, 2022, , .	3.3	5
272	Cold-induced neuromyotonia. Journal of Neurology, 1996, 243, 614-616.	3.6	4
273	Compound Muscle Action Potential: Pro. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, S103-S104.	1.2	4
274	The onset of ALS?. Clinical Neurophysiology, 2010, 121, 1709-1710.	1.5	4
275	Why is ALS so excited?. Clinical Neurophysiology, 2011, 122, 1689-1690.	1.5	4
276	Dropped head presentation in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 235-235.	1.7	4
277	Integrative biomarker discovery in neurodegenerative diseases. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2015, 7, 357-379.	6.6	4
278	Injuries of the Nerves of the Thorax. , 2015, , 525-543.		4
279	Ultrasound in ALS: Is it a sound method?. Clinical Neurophysiology, 2015, 126, 651-652.	1.5	4
280	Interplay of upper and lower motor neuron degeneration in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2017, 128, 2200-2204.	1.5	4
281	Celiac disease and a novel association with a multifocal acquired motor axonopathy (MAMA). Clinical Neurophysiology, 2017, 128, 1596-1598.	1.5	4
282	Plasma level of clubâ€cell (CC â€16) predicts outcome in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2018, 137, 233-237.	2.1	4
283	Concentric or monopolar electrode for jitter determination in orbicularis oculi. Clinical Neurophysiology, 2018, 129, 2552-2556.	1.5	4
284	A 15-minute session of direct current stimulation does not produce lasting changes in axonal excitability. Neurophysiologie Clinique, 2019, 49, 277-282.	2.2	4
285	Sensory modulation of fasciculation discharge frequency. Muscle and Nerve, 2019, 59, 688-693.	2.2	4
286	Societal costs and burden of hereditary transthyretin amyloidosis polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 89-96.	3.0	4
287	Surface electromyography for testing motor dysfunction in amyotrophic lateral sclerosis. Neurophysiologie Clinique, 2021, 51, 454-465.	2.2	4
288	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4

#	Article	IF	Citations
289	Unravelling Disease Presentation Patterns in ALS Using Biclustering for Discriminative Meta-Features Discovery. Lecture Notes in Computer Science, 2020, , 517-528.	1.3	4
290	Respiratory function tests in amyotrophic lateral sclerosis: The role of maximal voluntary ventilation. Journal of the Neurological Sciences, 2022, 434, 120143.	0.6	4
291	Influence of age and gender in the sensory nerve fibers excitability. Brain and Behavior, 2022, 12, e2467.	2.2	4
292	Progressive bulbospinal amyotrophy in triple A syndrome with AAAS gene mutation. Neurology, 2002, 59, 1823-1823.	1.1	3
293	Ventilation in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2006, 7, 3-4.	2.1	3
294	Impact of medical audit on electrodiagnostic medicine in polyneuropathy. Clinical Neurophysiology, 2011, 122, 2523-2529.	1.5	3
295	Lithium treatment in amyotrophic lateral sclerosis: do we have enough trials?. Expert Review of Neurotherapeutics, 2011, 11, 1693-1698.	2.8	3
296	Health Status Perspectives in Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases, 2017, 17, 323-329.	1.4	3
297	Assessing upper limb function with ALSFRS-R in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 445-448.	1.7	3
298	Modulation of sensory nerve fiber excitability by transcutaneous cathodal direct current stimulation. Neurophysiologie Clinique, 2019, 49, 385-390.	2.2	3
299	Cervical muscle weakness is a marker of respiratory dysfunction in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 323-324.	1.9	3
300	Disease modification in neurodegenerative diseases. Neurology, 2020, 94, 12-13.	1.1	3
301	Immobility and Fâ€waves: Impact on lower motor neuron excitability. Muscle and Nerve, 2020, 61, 480-484.	2.2	3
302	Family history of neurodegenerative disorders in patients with amyotrophic lateral sclerosis: population-based caseâ€“control study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 671-672.	1.9	3
303	Reliability of phrenic nerve conduction study: In healthy controls and in patients with primary lateral sclerosis. Clinical Neurophysiology, 2020, 131, 994-999.	1.5	3
304	Laryngeal electromyography in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 730-732.	1.9	3
305	Phrenic nerve study as outcome in clinical trials for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 9-13.	1.7	3
306	Benign fasciculations: A followâ€up study with electrophysiological studies. Muscle and Nerve, 2021, 64, 670-675.	2.2	3

#	Article	IF	Citations
307	Association of paraspinal and diaphragm denervation in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 0, , 1-4.	2.1	3
308	Peripheral neuropathy in ALS: phenotype association. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1133-1134.	1.9	3
309	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.7	3
310	Amyotrophic lateral sclerosis syndrome associated with connective tissue disease; improvement after immunosuppressive therapy. A long-term follow-up case. European Journal of Neurology, 1999, 6, 239-240.	3.3	2
311	Coexistence of transthyretin familial amyloid polyneuropathy and hereditary neuropathy with liability to pressure palsy. Clinical Neurology and Neurosurgery, 2012, 114, 1355-1357.	1.4	2
312	Does Awaji decrease diagnostic yield in ALS?. Muscle and Nerve, 2012, 46, 142-143.	2.2	2
313	Axial myoclonus after ischemic stroke. Neurology, 2015, 85, 654-654.	1.1	2
314	Voluntary control of a plegic limb during yawning. Journal of Neurology, 2018, 265, 433-435.	3.6	2
315	Motor unit recruitment in myopathy: The myopathic EMG reconsidered. Journal of Electromyography and Kinesiology, 2019, 45, 41-45.	1.7	2
316	Electric Field Distribution during Non-Invasive Electric and Magnetic Stimulation of the Cervical Spinal Cord. , 2019, 2019, 5898-5901.		2
317	Prognostic value of phrenic nerve conduction study in amyotrophic lateral sclerosis: Systematic review and meta-analysis. Clinical Neurophysiology, 2020, 131, 106-113.	1.5	2
318	Targeted next-generation sequencing study in familial ALS-FTD Portuguese patients negative for C9orf72 HRE. Journal of Neurology, 2020, 267, 3578-3592.	3.6	2
319	Compensatory metabolic and central respiratory drive mechanisms in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 1-3.	1.7	2
320	Patient Stratification Using Clinical and Patient Profiles: Targeting Personalized Prognostic Prediction in ALS. Lecture Notes in Computer Science, 2020, , 529-541.	1.3	2
321	Exercise following immobility increases lower motor neuron excitability: F-wave and H-reflex studies. Neurophysiologie Clinique, 2022, , .	2.2	2
322	A tentative interpretation of electromyographic regional differences in bulbar- and limb-onset ALS. Neurology, 2000, 54, 536-536.	1.1	1
323	Transcranial magnetic stimulation: Summary. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, S117-S118.	1.2	1
324	Longstanding right-hand weakness in a patient with myasthenia gravis. Muscle and Nerve, 2006, 34, 670-671.	2.2	1

#	Article	IF	Citations
325	Stratifying disease stages with different progression rates determined by electrophysiological tests in patients with amyotrophic lateral sclerosis. Muscle and Nerve, 2009, 40, 318-318.	2.2	1
326	An error of self-diagnosis--but what was the real diagnosis?. Practical Neurology, 2009, 9, 284-288.	1.1	1
327	Do We Have a Channel Solution for ALS?. EBioMedicine, 2015, 2, 1842-1843.	6.1	1
328	Comment on: The Awaji criteria are not always superior to the previous criteria: A metaâ€analysis. Muscle and Nerve, 2015, 52, 467-468.	2.2	1
329	Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis: Another view. Muscle and Nerve, 2015, 51, 460-461.	2.2	1
330	Prolongation of terminal latency of the phrenic nerve in amyotrophic lateral sclerosis â€“ Is it clinically useful, and what are the mechanisms?. Clinical Neurophysiology, 2017, 128, 2094.	1.5	1
331	Risk factors for onset of amyotrophic lateral sclerosis. European Journal of Neurology, 2017, 24, 9-10.	3.3	1
332	Cramps and vinpocetine in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 155-156.	1.7	1
333	The â€œsplit-legâ€•syndrome in ALS: specific or variable?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 615-616.	1.7	1
334	Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. Brain, 2019, 142, e67-e67.	7.6	1
335	Testing electrolyte supplementation for muscle cramp. Muscle and Nerve, 2019, 60, 499-500.	2.2	1
336	The â€˜neurophysiological indexâ€™ predicts survival in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2019, 130, 1684-1685.	1.5	1
337	Non-invasive evaluation of sudomotor function in patients with myasthenia gravis. Neurophysiologie Clinique, 2019, 49, 81-86.	2.2	1
338	Motor excitability measurements in early stage familial amyloid polyneuropathy: The influence of tafamidis treatment. Neurophysiologie Clinique, 2020, 50, 145-153.	2.2	1
339	Motor unit estimation by MRI: Integrating old and new ideas. Clinical Neurophysiology, 2020, 131, 1379-1380.	1.5	1
340	Predictive Medicine Using Interpretable Recurrent Neural Networks. Lecture Notes in Computer Science, 2021, , 187-202.	1.3	1
341	Î³' Fibrinogen as a Predictor of Survival in Amyotrophic Lateral Sclerosis. Frontiers in Cardiovascular Medicine, 2021, 8, 715842.	2.4	1
342	Reflex sympathetic dystrophy precipitated by brachial plexitis. Electromyography and Clinical Neurophysiology, 1998, 38, 459-61.	0.2	1

#	Article	IF	Citations
343	Thyroid dysfunction in Portuguese amyotrophic lateral sclerosis patients. Neurological Sciences, 2022, 43, 5625-5627.	1.9	1
344	Abrupt onset of progressive muscular atrophy. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 61-62.	1.2	0
345	NATURAL HISTORY OF YOUNG-ADULT AMYOTROPHIC LATERAL SCLEROSIS. Neurology, 2009, 73, 648-650.	1.1	0
346	Long-term survival in a patient with amyotrophic lateral sclerosis and respiratory presentation. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 396-397.	2.1	0
347	Patrikios syndrome in two patients with treatable flail-leg weakness. Journal of Clinical Neuroscience, 2012, 19, 318-321.	1.5	0
348	Estimating the value of estimation. Clinical Neurophysiology, 2012, 123, 1904-1905.	1.5	0
349	Split-hand to diagnosis shot. Clinical Neurophysiology, 2013, 124, 219-220.	1.5	0
350	Nerve excitabitability and fasciculations. Clinical Neurophysiology, 2013, 124, 1925.	1.5	0
351	Reply. Muscle and Nerve, 2013, 47, 620-621.	2.2	0
352	Young slow-progressing ALS patients are at higher risk of inappropriate and disease-quickening surgeries. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 621-621.	1.7	0
353	A handful of promises. Clinical Neurophysiology, 2014, 125, 5.	1.5	0
354	Seasons and ALS time of death. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 291-295.	1.7	0
355	Concentric and monopolar needle for jitter estimation in orbicularis oculi. Journal of the Neurological Sciences, 2017, 381, 1092.	0.6	0
356	Neurophysiologic characterization of periodic paralysis episode in a patient with Andersen-Tawil syndrome. Clinical Neurophysiology, 2018, 129, 558-559.	1.5	0
357	Fasciculation: Does distance really matter?. Clinical Neurophysiology, 2018, 129, 462-463.	1.5	0
358	Guide the EMG lines. Clinical Neurophysiology, 2019, 130, 1682-1683.	1.5	0
359	Lambertâ€“Eaton Myasthenic Syndrome Plus. Journal of Clinical Neuromuscular Disease, 2019, 21, 119-121.	0.7	0
360	Fasciculations: Opening Pandoraâ€™s box. Clinical Neurophysiology, 2020, 131, 239-240.	1.5	0

#	Article	IF	Citations
361	Measuring spinal presynaptic inhibition in human subjects. Clinical Neurophysiology, 2020, 131, 1966-1967.	1.5	0
362	Modulation of neuromuscular transmission using transcutaneous direct currents: An exploratory study. Neurophysiologie Clinique, 2020, 50, 315-320.	2.2	0
363	Respiratory Neurophysiology in Intensive Care Unit. Journal of Clinical Neurophysiology, 2020, 37, 208-210.	1.7	0
364	Authorsâ€™ reply: Differences between South African and Portuguese ALS cohorts from an environmental perspective. Journal of the Neurological Sciences, 2020, 414, 116932.	0.6	0
365	Needling the future in ALS. Clinical Neurophysiology, 2020, 131, 1973-1974.	1.5	0
366	ALS and fertility: does ALS affect number of children patients have?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 94-100.	1.7	0
367	In the spiral of history: SARS-Cov-2 infection. Clinical Neurophysiology, 2021, 132, 1959-1960.	1.5	0
368	Levosimendan for amyotrophic lateral sclerosis. Lancet Neurology, The, 2021, 20, 775-777.	10.2	0
369	Reply to the letter from Gazulla. European Journal of Neurology, 2022, 29, e3-e4.	3.3	0
370	Non-invasive Spinal Cord Stimulation: Relevance of Modelling Studies in Clinical Protocol Design. IFMBE Proceedings, 2020, , 1767-1773.	0.3	0
371	Impact of SARS-CoV-2 Infection Among Non-Invasive Ventilated ALS Patients. Journal of Neuromuscular Diseases, 2022, 9, 257-259.	2.6	0
372	Motor neuron disease in three asymptomatic pVal50Met TTR gene carriers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, , 1-3.	1.7	0
373	Mimicking Amyotrophic Lateral Sclerosis: A Case of a Spinal Dural Arteriovenous Fistula. Case Reports in Neurology, 2022, 13, 802-806.	0.7	0
374	Imaging motor unit territory. Clinical Neurophysiology, 2022, , .	1.5	0
375	Monitoring disease onset in amyotrophic lateral sclerosis. Nature Reviews Neurology, 0, , .	10.1	0